Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × NSCLC × osimertinib × Clear all

Phase

Status

Unknown 2 Recruiting 2 Completed 2 Active not recruiting 2 Withdrawn 1 Terminated 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 16 Lung Neoplasms 6 Small Cell Lung Carcinoma 1 Resectable Non-small Cell Lung Cancer 1 Recurrence 1 Rare Tumour 1 Neoplastic Cells, Circulating 1 Neoplasm, Residual 1 NSCLC 1 Meningeal Carcinomatosis 1 Brain Neoplasms 1

Interventions

Surgical Procedures, Operative 2 Drug Therapy 2 Carboplatin 2 toripalimab 1 tislelizumab 1 surufatinib 1 osimertinib 1 lorlatinib 1 anlotinib 1 Radiotherapy 1 Radiosurgery 1 Platinum Compounds 1 Pemetrexed 1 Paclitaxel 1 Neoadjuvant Therapy 1 Diphenhydramine 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Chemoradiotherapy 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07376382 2026-02-02

SYNSTAR-02

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡